CN113959822B - Diluent and oxidant for measuring iodine content in urine by peroxyacetic acid oxidation method and application - Google Patents
Diluent and oxidant for measuring iodine content in urine by peroxyacetic acid oxidation method and application Download PDFInfo
- Publication number
- CN113959822B CN113959822B CN202111275912.6A CN202111275912A CN113959822B CN 113959822 B CN113959822 B CN 113959822B CN 202111275912 A CN202111275912 A CN 202111275912A CN 113959822 B CN113959822 B CN 113959822B
- Authority
- CN
- China
- Prior art keywords
- urine
- iodine
- diluent
- oxidant
- peroxyacetic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 title claims abstract description 94
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 title claims abstract description 77
- 239000011630 iodine Substances 0.000 title claims abstract description 77
- 229910052740 iodine Inorganic materials 0.000 title claims abstract description 77
- 210000002700 urine Anatomy 0.000 title claims abstract description 58
- 239000007800 oxidant agent Substances 0.000 title claims abstract description 45
- 239000003085 diluting agent Substances 0.000 title claims abstract description 40
- 238000000034 method Methods 0.000 title claims abstract description 33
- 230000001590 oxidative effect Effects 0.000 title claims abstract description 28
- 230000003647 oxidation Effects 0.000 title claims abstract description 26
- 238000007254 oxidation reaction Methods 0.000 title claims abstract description 26
- 239000007853 buffer solution Substances 0.000 claims abstract description 20
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims abstract description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 16
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229960002303 citric acid monohydrate Drugs 0.000 claims abstract description 13
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims abstract description 12
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000005557 antagonist Substances 0.000 claims abstract description 8
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims abstract description 8
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims abstract description 8
- 235000019799 monosodium phosphate Nutrition 0.000 claims abstract description 8
- 239000001103 potassium chloride Substances 0.000 claims abstract description 8
- 235000011164 potassium chloride Nutrition 0.000 claims abstract description 8
- 239000011780 sodium chloride Substances 0.000 claims abstract description 8
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims abstract description 8
- 238000001179 sorption measurement Methods 0.000 claims abstract description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000000243 solution Substances 0.000 claims description 32
- 238000010790 dilution Methods 0.000 claims description 12
- 239000012895 dilution Substances 0.000 claims description 12
- 239000003755 preservative agent Substances 0.000 claims description 8
- 239000003153 chemical reaction reagent Substances 0.000 claims description 6
- 230000002335 preservative effect Effects 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 5
- 229960002816 potassium chloride Drugs 0.000 claims description 3
- 239000008213 purified water Substances 0.000 claims description 3
- 229960002668 sodium chloride Drugs 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 2
- 239000012089 stop solution Substances 0.000 claims description 2
- 230000002485 urinary effect Effects 0.000 claims description 2
- 238000001514 detection method Methods 0.000 abstract description 51
- 230000035945 sensitivity Effects 0.000 abstract description 7
- 239000007788 liquid Substances 0.000 abstract description 4
- 231100000053 low toxicity Toxicity 0.000 abstract description 3
- 238000012360 testing method Methods 0.000 description 19
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 238000011161 development Methods 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 7
- -1 peroxyacetic acid tetramethyl benzidine Chemical compound 0.000 description 7
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 6
- 238000002798 spectrophotometry method Methods 0.000 description 6
- 238000001914 filtration Methods 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 229960004106 citric acid Drugs 0.000 description 4
- 238000012417 linear regression Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000036541 health Effects 0.000 description 3
- 238000006479 redox reaction Methods 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 3
- 206010067997 Iodine deficiency Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- ROOXNKNUYICQNP-UHFFFAOYSA-N ammonium persulfate Chemical compound [NH4+].[NH4+].[O-]S(=O)(=O)OOS([O-])(=O)=O ROOXNKNUYICQNP-UHFFFAOYSA-N 0.000 description 2
- TUFLVBXBZSNFCZ-UHFFFAOYSA-N arsenic cerium Chemical compound [As].[Ce] TUFLVBXBZSNFCZ-UHFFFAOYSA-N 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 235000006479 iodine deficiency Nutrition 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 229940033663 thimerosal Drugs 0.000 description 2
- HJTAZXHBEBIQQX-UHFFFAOYSA-N 1,5-bis(chloromethyl)naphthalene Chemical compound C1=CC=C2C(CCl)=CC=CC2=C1CCl HJTAZXHBEBIQQX-UHFFFAOYSA-N 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- PQRTVVJRFXOOGJ-UHFFFAOYSA-N O.O.[Na].[Na].[Na].C(CC(O)(C(=O)O)CC(=O)O)(=O)O Chemical compound O.O.[Na].[Na].[Na].C(CC(O)(C(=O)O)CC(=O)O)(=O)O PQRTVVJRFXOOGJ-UHFFFAOYSA-N 0.000 description 1
- 208000024799 Thyroid disease Diseases 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 229910001870 ammonium persulfate Inorganic materials 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 238000001095 inductively coupled plasma mass spectrometry Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000036632 reaction speed Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/38—Diluting, dispersing or mixing samples
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The invention provides a diluent, an oxidant and application for measuring the iodine content in urine by a peroxyacetic acid oxidation method, wherein the diluent comprises a buffer solution and an iodine adsorption antagonist, and the buffer solution comprises the following components: the mass concentration is 20-30 g/L citric acid monohydrate, 10-15 g/L trisodium citrate dihydrate, 4-5% sodium dihydrogen phosphate and 4-5% disodium hydrogen phosphate; iodine adsorption antagonists include: the mass concentration is 2-3% of sodium chloride and 2-3% of potassium chloride; the pH value of the diluent is 2.5-2.95. The oxidant comprises 4.5 to 6 percent of peroxyacetic acid, 28.2 to 28.65 percent of hydrogen peroxide and water. The advantages are that: the diluent has good stability, low toxicity, better linear relation for urine detection with low concentration iodine content and higher accuracy; the oxidant can obtain a standard curve with good linearity, no stopping liquid is needed, and the oxidant has good sensitivity and accuracy in the detection range of 0-500 mug/L.
Description
Technical Field
The invention relates to the field of in-vitro diagnosis and detection, in particular to a diluent and an oxidant for measuring the content of urine iodine by a peroxyacetic acid oxidation method and application thereof.
Background
Iodine is a trace element essential for the synthesis of various systems of human body, especially thyroid hormone and the development of nervous system, and can be taken along with food, drinking water, salt and the like when entering the body, wherein 90% of iodine is discharged from kidney. Urine iodine can generally reflect the amount of iodine taken by a person and the amount of iodine contained in blood. Iodine deficiency and excess may cause thyroid disorders, constitute a series of lesions to the human body, and in particular iodine deficiency in pregnant women may lead to irreversible mental retardation and mental dyskinesia in the fetus or infant. The urine iodine level is an important index for measuring the iodine nutrition condition of the crowd, and is widely applied to clinical diagnosis and treatment, medical care, disease prevention and treatment and other aspects of hospitals.
Currently, the urine iodine detection method mainly comprises an inductively coupled plasma-mass spectrometry, a neutron digestion method, a spectrophotometry method, a gas chromatography method and the like. The current standard method for detecting the urine iodine in China is an arsenic-cerium catalytic spectrophotometry (national standard method) newly issued by the original health department in 2016, and the method has the advantages of good repeatability, strong anti-interference capability, high sensitivity and the like, but the urine sample is required to be digested by ammonium persulfate, the time consumption is long, arsenic trioxide in the reagent is easy to pollute the environment and cause harm to human health, and the method has more manual steps, complex operation and certain limitations and dangers.
Luo Xiuxia et al (volume 41, 4 of month 2 in 2020, journal of International inspection medicine) discuss a method and a technology for measuring the iodine level in urine by a peroxyacetic acid oxidation method, and prove that the method for measuring the iodine in urine by the peroxyacetic acid oxidation method has the advantages of simple operation, good standard curve, good linear relation, high accuracy, good specificity and good repeatability, and is a method for rapidly detecting the iodine in urine, which is worth popularizing.
The existing kit has the problems of large deviation of detection value of low-concentration iodine solution, low detection value of high concentration, narrow concentration detection range, insufficient detection sensitivity and the like, and meanwhile, the diluent of the existing kit is usually filled with the thimerosal or sodium azide as a preservative, but the sodium azide is extremely toxic and the thimerosal toxicity is not obvious. The accuracy and the sensitivity of the detection kit for the peroxyacetic acid oxidation method on the market can not reach the detection effect of the arsenic cerium catalytic spectrophotometry (national standard method), and the popularization of the peroxyacetic acid oxidation method in urine iodine detection is affected.
Disclosure of Invention
Aiming at the problems of large deviation of detection value of the existing peroxyacetic acid oxidation method detection reagent on low-concentration iodine solution, low detection value of high concentration, narrow concentration detection range, insufficient detection sensitivity and the like, the invention provides a diluent, an oxidant and application for measuring the content of urine iodine.
The technical scheme of the invention is as follows:
a diluted solution for measuring urine iodine by a peroxyacetic acid oxidation method, which comprises a buffer solution and an iodine adsorption antagonist, wherein the buffer solution comprises the following components: the mass concentration is 20-30 g/L citric acid monohydrate, 10-15 g/L trisodium citrate dihydrate, 4-5% sodium dihydrogen phosphate and 4-5% disodium hydrogen phosphate; iodine adsorption antagonists include: the mass concentration is 2-3% of sodium chloride and 2-3% of potassium chloride; the pH value of the diluent is 2.5-2.95.
Further comprises a preservative, wherein the preservative is proclin-300 with the mass concentration of 1-2%.
Further, citric acid monohydrate or trisodium citrate dihydrate is also used to adjust the pH of the diluent.
The preparation method of the diluent for measuring the content of urine iodine by the peroxyacetic acid oxidation method is used for preparing the diluent and comprises the following steps of: weighing citric acid monohydrate, sodium chloride, potassium chloride, trisodium citrate dihydrate, sodium dihydrogen phosphate, disodium hydrogen phosphate and proclin-300 according to a proportion, dissolving with purified water, fixing the volume to a preparation volume, and uniformly stirring; the pH value of the prepared dilution is measured, and the pH value is adjusted to be below 3.0 by using citric acid monohydrate or trisodium citrate dihydrate solution.
The oxidant for measuring the iodine content in urine by the peroxyacetic acid oxidation method comprises 4.5-6% of peroxyacetic acid, 28.2-28.65% of hydrogen peroxide by mass concentration and the balance of water.
The use of the diluted solution for measuring the content of urine iodine by the peroxyacetic acid oxidation method in measuring the content of urine iodine.
Furthermore, the oxidant for measuring the iodine content in urine by the peroxyacetic acid oxidation method is used without using a stop solution.
The invention has the advantages that: the diluent adopts a buffer system of two combinations of citric acid and phosphoric acid, has stronger buffer capacity, good stability and low toxicity, does not react with components of a urine sample, does not reduce the content of iodine in urine, is filtered by a filtering device after diluting the urine sample, participates in the redox reaction of peroxyacetic acid and 3, 5-tetramethylbenzidine, provides a stable buffer environment for the redox reaction, ensures the smooth progress of the redox reaction, and has higher linear relation and higher accuracy in the urine detection of low-concentration iodine content. The oxidant not only can keep the original sensitivity of the oxidant, but also has a good linear standard curve, and meanwhile, no stopping liquid is needed, so that the detection step of the peroxyacetic acid oxidation method is simplified, and the detection is more accurate and quicker; the coverage range of the detection concentration is wider, and the detection concentration has good sensitivity and accuracy in the detection range of 0-500 mug/L.
Drawings
FIG. 1 is a graph showing the OD value of the dilutions of the present invention versus the iodine solutions of different concentrations;
FIG. 2 is a graph showing the OD value of the diluent with pH 3.0 or more for iodine solutions with different concentrations;
FIG. 3 is a graph showing the standard curve of the detection of iodine solution with different concentrations by using the oxidizing agent of the present invention;
FIG. 4 is a graph of the standard curve of detection of oxidizing agent with peroxyacetic acid content < 0.3% versus iodine solution of different concentrations;
FIG. 5 is a standard curve of the detection of iodine solutions of different concentrations for oxidants with peroxyacetic acid content > 8%.
Detailed Description
The following description of the technical solutions in the embodiments of the present invention will be clear and complete, and it is obvious that the described embodiments are only some embodiments of the present invention, but not all embodiments. All other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, are intended to be within the scope of the invention.
The invention relates to a diluent and an oxidant for detecting the iodine content in urine by a peroxyacetic acid tetramethyl benzidine oxidation chromogenic method.
The diluent comprises: the mass concentration is 20-30 g/L citric acid monohydrate, 10-15 g/L citric acid trisodium dihydrate, 4-5% sodium dihydrogen phosphate, 4-5% disodium hydrogen phosphate, 2-3% sodium chloride, 2-3% potassium chloride, 1-2% proclin-300 and the pH value is 2.5-2.95.
The oxidizing agent comprises: the mass concentration is 4.5-6% of peroxyacetic acid, 28.2-28.65% of hydrogen peroxide and the balance of water. The oxidant is simple in composition and is less affected by other chemical components.
The diluents in the present invention include buffers, iodine adsorption antagonists and preservatives.
The buffer solution comprises a buffer system consisting of 20-30 g/L citric acid monohydrate, 10-15 g/L trisodium citrate dihydrate, 4-5% sodium dihydrogen phosphate and 4-5% disodium hydrogen phosphate, wherein the citric acid monohydrate and trisodium citrate dihydrate of the citric acid buffer system in the buffer solution have higher use concentration and have the functions of fresh keeping, antioxidation and the like, and meanwhile, the buffer solution adopts a buffer system of two combinations of citric acid and phosphoric acid, so that the buffer solution has more ion types, higher concentration and stronger buffer capability.
The iodine adsorption antagonist comprises sodium chloride with the mass concentration of 2-3% and potassium chloride with the mass concentration of 2-3%, and has certain effects of sterilizing and keeping cell osmotic pressure balance.
The proclin-300 is used as a preservative added in the diluent provided by the invention, is an efficient, low-toxicity and special bacteriostatic agent for in-vitro diagnostic reagents, is used for replacing merthiolate, sodium azide and gentamicin preservatives, can be stored at room temperature for a long time, and has little harm to human health and environment.
The pH value of the diluent is 2.5-2.95, so that the accuracy of detecting low-concentration urine iodine by the peroxyacetic acid detection method can be improved.
The preparation of the diluent comprises the following steps: weighing citric acid monohydrate, sodium chloride, potassium chloride, trisodium citrate dihydrate, sodium dihydrogen phosphate, disodium hydrogen phosphate and proclin-300 according to the proportion, dissolving with purified water, fixing the volume to the preparation volume, and uniformly stirring; the pH value of the prepared diluent is measured, and the pH value of the diluent is adjusted to be below 3.0 by using a small amount of citric acid monohydrate or trisodium citrate dihydrate solution.
The oxidant is a key reagent of a peroxyacetic acid tetramethyl benzidine oxidation color development method, and the content proportion of the peroxyacetic acid is moderate, so that the color development reaction is not too strong or weak; generating blue color development substances under the oxidation action of iodine in urine by the oxidant and 3,3', 5' -tetramethyl benzidine (TMB) in the color development liquid; the blue color development is in direct proportion to the concentration of iodine in urine. Within a certain range, the higher the concentration of iodine, the faster the reaction speed, and the more blue products; when the color developing agent and the oxidant are contacted with urine to be detected, the darker the color of the obtained solution is, the higher the concentration of iodide ions is, the magnitude of absorbance is reflected according to the shade of the color of the solution, and the concentration of the iodide ions is further obtained.
Example 1
The following dilutions were used as examples for comparative verification tests of standard iodine solutions:
the buffer solution prepared by the invention and iodine solutions with different concentrations (0, 50ug/L, 100ug/L, 150ug/L, 200ug/L, 250ug/L, 300 ug/L) are filtered by a filter device and then participate in the oxidation color reaction of the peroxyacetic acid tetramethyl benzidine; iodine of the iodine solution with each concentration reacts with an oxidant and a chromogenic solution which are added into a cuvette in a buffer system of the diluent to carry out chromogenic reaction, and finally, the absorbance value is measured by ultraviolet spectrophotometry. The test is carried out under the same condition by comparing the diluent in the commercial peracetic acid kit, and the comparative test is carried out by taking the diluent of the kit for measuring the urinary iodine by the peracetic acid method of the golden field diagnosis technology limited company in Beijing as an example, wherein the diluted general components are citric acid and magnesium chloride, and the pH=3-6.5, and the diluent with the pH more than or equal to 3.0 is abbreviated as the diluent.
The testing process is completed by the following steps:
s1, placing the diluent, iodine solution or urine with various concentrations, a cuvette, a urine filter device, an oxidant and a color development solution in corresponding positions of a full-automatic urine iodine detector (LTS-ND 180, zhuhai Lituo Biotechnology Co., ltd.);
s2, starting a full-automatic urine iodine detector (LTS-ND 180), entering a homepage of the instrument, clicking a 'loading diluent' according to the operation description of the urine iodine detector, loading a diluent pipeline, clicking a homepage icon, entering a homepage of the next step, debugging the instrument, a liquid path module, a vertical progressive machine, clicking a sample adding needle to a vertical position, clicking a cleaning inner wall, clicking an outer wall, cleaning, resetting, returning, entering a homepage, and testing a sample;
s3, after entering a sample test page, adding a number (the number of the detected samples) and an initial sample disk number of 1, confirming an application, and clicking to start detection;
and S4, after the detection is finished, the concentration of the detected iodine can be directly read from the detection result.
TABLE 1 test of the dilutions of the invention and of the dilutions having a pH > 3.0 on iodine solution
As shown in Table 1, FIG. 1 and FIG. 2, the absorbance values measured by the iodine solutions of the above concentrations and the corresponding iodine solution concentrations were fitted by linear regression to obtain regression coefficients R 2 And a regression equation; it can be seen that the linear regression coefficient r of the diluent detection standard curve of the invention 2 R of diluent with ratio pH = 0.9996 > 3.0 2 Higher = 0.9909, better linearity, and more accurate experimental results on iodine solution.
Example 2
The following test experiments were performed using a urine standard as an example of a diluent:
adding the prepared buffer solution and urine standard substances (14.6 ug/L, 29.2ug/L, 58.5ug/L, 117ug/L and 234 ug/L) with different concentrations into a filter device together, and participating in the oxidation color development reaction of the tetramethyl benzidine peroxyacetate after the filtration of the filter device; iodine of the iodine solution with each concentration reacts with an oxidant and a chromogenic solution which are added into a cuvette in a buffer system of the diluent to carry out chromogenic reaction, and finally, the absorbance value is measured by ultraviolet spectrophotometry. The test was performed under the same conditions as in example 1, comparing the commercial diluted peroxyacetic acid kit with a pH of 3.0 or more.
Substituting the absorbance value measured by the iodine of the urine clinical sample into the linear regression equation to calculate the concentration of the urine.
TABLE 2 use of the dilutions of the present invention in the peracetic acid urine iodine detection assay
Table 3 dilution with pH 3.0 or more for peracetic acid urine iodine detection test
Example 3
The following repeated tests were performed on low concentration urine clinical samples using dilutions as an example:
adding the prepared buffer solution and the low-concentration urine clinical sample into a filtering device together, and participating in oxidation chromogenic reaction of the tetramethyl benzidine peroxyacetate after the filtration of the filtering device; iodine of the iodine solution with each concentration reacts with an oxidant and a chromogenic solution which are added into a cuvette in a buffer system of the diluent to carry out chromogenic reaction, and finally, the absorbance value is measured by ultraviolet spectrophotometry. The test was performed under the same conditions as in example 1, comparing the commercial diluted peroxyacetic acid kit with a pH of 3.0 or more.
TABLE 4 test of the dilutions of the present invention and dilutions having a pH of 3.0 or more on clinical samples
As can be seen from the experimental data of examples 1-3:
the detection value of low-concentration iodine in a standard curve of diluent detection with the commercial pH value of more than or equal to 3.0 is lower, the value of a detected clinical sample is higher, and finally, the detected low-concentration urine standard substance (< 50 ug/L) and the low-concentration urine clinical sample are higher than those of an experiment.
Example 4
The following is an example of the accuracy of the test of standard iodine solution under the same test conditions for the oxidizing agent of the present invention and the oxidizing agents commercially available in different peroxyacetic acid contents, and the test procedure is the same as in example 1. The detection results are as follows:
TABLE 5 Standard Curve measurement results of the iodine content of urine measured with different Peroxyacetic acid content oxidants
Specific detection standard curves are shown in figures 3, 4 and 5, and can be seen as the linear regression line r of the standard curves of the oxidant and the matched reagent thereof 2 =0.9987, the detection concentration range can reach 0-500 ug/L; and r in the content of peracetic acid in the oxidant is less than 0.3% 2 Although the detection range can reach 0-500 ug/L, the detection value of 50ug/L iodine solution is lower; r of the content of peracetic acid in the oxidant is more than 8% 2 = 0.9562, the linearity is poor, and the detection range can only reach 0-300 ug/L. Therefore, the detection result of the oxidizing agent of the present invention is optimal.
Example 5
The following is an example 1 of the accuracy of the test of the standard urine material under the same test conditions for the oxidizing agent of the present invention and the oxidizing agents commercially available in different peroxyacetic acid contents. The detection results are as follows: TABLE 6 detection results of different Peroxyacetic acid content oxidants on urine standards
It can be seen that the detection results of the oxidant provided by the invention on BW09108t (89.8 ug/L) and BW09110y (228 ug/L) standard products are even and accurate, the concentration of the detection standard products with the peracetic acid content of less than 0.3% in the oxidant is higher, and the detection results with the peracetic acid content of more than 8% in the oxidant are lower and even and inaccurate.
Example 6
The following is an example of the accuracy of the test of clinical urine samples under the same test conditions with the oxidizing agents of the present invention and commercially available oxidizing agents of different peracetic acid content, and the test procedure is the same as in example 1. The detection results are as follows:
TABLE 7 detection results of oxidizer urine clinical samples for different amounts of peroxyacetic acid
The detection results of the oxidizing agent for urine with different concentrations are stable, the detection results of the oxidizing agent for urine with low concentration, which contain less than 0.3% of peracetic acid, are higher, and the detection results of the oxidizing agent for urine with low concentration, which contain more than 8% of peracetic acid, are lower, and the detection results are unstable and even and inaccurate.
The foregoing description is only illustrative of the preferred embodiment of the present invention, and is not to be construed as limiting the invention, but is to be construed as limiting the invention to any and all simple modifications, equivalent variations and adaptations of the embodiments described above, which are within the scope of the invention, may be made by those skilled in the art without departing from the scope of the invention.
Claims (6)
1. A diluent for measuring the iodine content of urine by a peroxyacetic acid oxidation method, which is characterized by comprising a buffer solution and an iodine adsorption antagonist, wherein the buffer solution comprises: the mass concentration is 20-30 g/L citric acid monohydrate, 10-15 g/L trisodium citrate dihydrate, 4-5% sodium dihydrogen phosphate and 4-5% disodium hydrogen phosphate; iodine adsorption antagonists include: the mass concentration is 2-3% of sodium chloride and 2-3% of potassium chloride; the pH value of the diluent is 2.5-2.95.
2. The diluted solution for measuring the iodine content in urine by the peroxyacetic acid oxidation method according to claim 1, which further comprises a preservative, wherein the preservative is proclin-300 with the mass concentration of 1-2%.
3. A method for preparing a diluent for measuring the iodine content in urine by a peracetic acid oxidation method, comprising the steps of: weighing citric acid monohydrate, sodium chloride, potassium chloride, trisodium citrate dihydrate, sodium dihydrogen phosphate, disodium hydrogen phosphate and proclin-300 according to a proportion, dissolving with purified water, fixing the volume to a preparation volume, and uniformly stirring; the pH value of the prepared dilution is measured, and the pH value is adjusted to be below 3.0 by using citric acid monohydrate or trisodium citrate dihydrate solution.
4. An oxidant for measuring the content of urine iodine by a peroxyacetic acid oxidation method is characterized in that: comprises 4.5 to 6 percent of peroxyacetic acid, 28.2 to 28.65 percent of hydrogen peroxide and the balance of water.
5. Use of a dilution of the peroxyacetic acid oxidation process of claim 1 or 2 for determining the urinary iodine content.
6. Use according to claim 5, characterized in that: the method according to claim 4, wherein the reagent for measuring the iodine content in urine is used without using a stop solution.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111275912.6A CN113959822B (en) | 2021-10-29 | 2021-10-29 | Diluent and oxidant for measuring iodine content in urine by peroxyacetic acid oxidation method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111275912.6A CN113959822B (en) | 2021-10-29 | 2021-10-29 | Diluent and oxidant for measuring iodine content in urine by peroxyacetic acid oxidation method and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113959822A CN113959822A (en) | 2022-01-21 |
| CN113959822B true CN113959822B (en) | 2024-02-20 |
Family
ID=79468599
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111275912.6A Active CN113959822B (en) | 2021-10-29 | 2021-10-29 | Diluent and oxidant for measuring iodine content in urine by peroxyacetic acid oxidation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113959822B (en) |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1811394A (en) * | 2006-03-07 | 2006-08-02 | 北京中生金域诊断技术有限公司 | Urine iodine test reagent kit |
| TW200630471A (en) * | 2004-11-05 | 2006-09-01 | Cabot Microelectronics Corp | CMP composition containing surface-modified abrasive particles |
| CN104089956A (en) * | 2014-07-21 | 2014-10-08 | 陕西省地方病防治研究所 | Quick water iodine testing kit and testing method thereof |
| WO2015153258A1 (en) * | 2014-03-31 | 2015-10-08 | Iotech International, Llc | Stable compositions of uncomplexed iodine and methods of use |
| CN105004719A (en) * | 2015-07-21 | 2015-10-28 | 杨先锋 | Urine iodine determination kit and applications thereof |
| CN105424934A (en) * | 2015-10-30 | 2016-03-23 | 山东博科生物产业有限公司 | N-acetyl-beta-D glucosidase reagent and detection method |
| CN106546586A (en) * | 2016-11-09 | 2017-03-29 | 安徽惠邦生物工程股份有限公司 | The detectable of content of iodine in a kind of vitro detection urine |
| CN109187399A (en) * | 2018-07-23 | 2019-01-11 | 华侨大学 | A kind of method of Peracetic acid and content of hydrogen peroxide in quick measurement solution |
| CN110006881A (en) * | 2019-04-01 | 2019-07-12 | 深圳大学 | In urine in the detection kit and urine of content of iodine content of iodine detection method |
| CN110927153A (en) * | 2019-12-11 | 2020-03-27 | 南京医科大学 | Method for quantitatively or semi-quantitatively detecting concentration of iodide ions in urine |
-
2021
- 2021-10-29 CN CN202111275912.6A patent/CN113959822B/en active Active
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200630471A (en) * | 2004-11-05 | 2006-09-01 | Cabot Microelectronics Corp | CMP composition containing surface-modified abrasive particles |
| CN1811394A (en) * | 2006-03-07 | 2006-08-02 | 北京中生金域诊断技术有限公司 | Urine iodine test reagent kit |
| WO2015153258A1 (en) * | 2014-03-31 | 2015-10-08 | Iotech International, Llc | Stable compositions of uncomplexed iodine and methods of use |
| CN104089956A (en) * | 2014-07-21 | 2014-10-08 | 陕西省地方病防治研究所 | Quick water iodine testing kit and testing method thereof |
| CN105004719A (en) * | 2015-07-21 | 2015-10-28 | 杨先锋 | Urine iodine determination kit and applications thereof |
| CN105424934A (en) * | 2015-10-30 | 2016-03-23 | 山东博科生物产业有限公司 | N-acetyl-beta-D glucosidase reagent and detection method |
| CN106546586A (en) * | 2016-11-09 | 2017-03-29 | 安徽惠邦生物工程股份有限公司 | The detectable of content of iodine in a kind of vitro detection urine |
| CN109187399A (en) * | 2018-07-23 | 2019-01-11 | 华侨大学 | A kind of method of Peracetic acid and content of hydrogen peroxide in quick measurement solution |
| CN110006881A (en) * | 2019-04-01 | 2019-07-12 | 深圳大学 | In urine in the detection kit and urine of content of iodine content of iodine detection method |
| CN110927153A (en) * | 2019-12-11 | 2020-03-27 | 南京医科大学 | Method for quantitatively or semi-quantitatively detecting concentration of iodide ions in urine |
Non-Patent Citations (7)
| Title |
|---|
| Odre|ivanje persir}etne kiseline i vodonik-peroksida u sme{i;Milanka Bodiroga等;《VOJNOSANITETSKI PREGLED》;20021231;第3卷(第59期);第277-279页 * |
| 不同缓冲体系对分散染料高温高压染色的影响;钟丽华等;《印染与整理》(第6期);第20-26页 * |
| 二氧化氯漂白过程 pH 缓冲体系的构建;王伦等;《工艺技术》;第29卷(第10期);第9-11页 * |
| 基于不同缓冲体系的纤维素酶活力及其稳定性研究;李倩等;《染整技术》;第38卷(第2期);第4-8页 * |
| 尿液碘两点速率法的建立及评价;吴元健;;临床检验杂志;20110715;29(4);第247-249页 * |
| 碘化物的光分析研究进展;王瑞琪等;《重庆工商大学学报（自然科学版）》;20030930;第20卷(第3期);第77-79页 * |
| 陈家伦等.《临床内分泌学》.上海科学技术出版社,2012,第313页. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113959822A (en) | 2022-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Robertson et al. | Calcium measurements in serum and plasma—total and ionized | |
| Bowers et al. | Kinetic serum creatinine assays. II. A critical evaluation and review. | |
| EP1881328B1 (en) | Method of determining iron concentration | |
| CN104714040B (en) | Glucose in serum oxidase double reagent assay method | |
| EP0097472B1 (en) | Method of determining calcium in a fluid sample | |
| CN112662736A (en) | Preparation method of uric acid kit for quickly and simply eliminating interference of calcium dobesilate and etamsylate medicines in serum | |
| Bäck et al. | A simple chemical method for the quantification of the contrast agent iohexol, applicable to glomerular filtration rate measurements | |
| CN108613976B (en) | Direct bilirubin detection kit | |
| CN110006881A (en) | In urine in the detection kit and urine of content of iodine content of iodine detection method | |
| CN113959822B (en) | Diluent and oxidant for measuring iodine content in urine by peroxyacetic acid oxidation method and application | |
| US4393142A (en) | Assay method and reagent for the determination of chloride | |
| CN111289501A (en) | Kit for detecting NO based on indirect colorimetric method and preparation and use methods thereof | |
| JP4151023B2 (en) | Calcium measuring reagent and measuring method | |
| CN105842437A (en) | Kit for detecting D-3-hydroxybutyric acid and preparation method of kit | |
| CN114487446A (en) | Stable apolipoprotein B determination kit with strong anti-interference capability | |
| DK169415B1 (en) | Process and reagent for quantitative photometric determination of phosphorus in body fluids | |
| JP3220378B2 (en) | Method and reagent for quantification of total protein | |
| Steinmetz et al. | Modified aca method for determination of iron chelated by deferoxamine and other chelators. | |
| CN112129949A (en) | Retinol binding protein detection kit, preparation method and use method thereof | |
| WO2005024423A2 (en) | A method for qualitative and/or quantitative detection of polyethylene glycols in biological fluids | |
| JP2007240163A (en) | Measuring method of protein in sample and measuring reagent | |
| CN111830259B (en) | Alpha 1 microglobulin determination kit | |
| CN114705640A (en) | High-sensitivity serum zinc determination reagent with strong anti-interference capability and preparation method thereof | |
| Brody et al. | Centrifugal analyzer method for total bilirubin in serum by use of diazotized 2-chloroaniline-5-sulfonic acid. | |
| Liu et al. | Interference of sodium azide with measurement of serum uric acid by the direct acid ferric reduction procedure. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |